Compare Stocks: DBVT, GMTX, ABCL, and IDYA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.32 -2.2%	$7.27	$2.74 ▼ $12.15	$3.47B	1.2	10.20 million shs	4.54 million shs
DBVT DBV Technologies	$14.55 +2.2%	$15.02	$8.70 ▼ $26.18	$914.83M	-0.93	363,415 shs	124,583 shs
GMTX Gemini Therapeutics	$79.81 +1.2%	$75.58	$1.16 ▼ $14.10	$3.46B	-0.12	189,291 shs	370,353 shs
IDYA IDEAYA Biosciences	$39.67 +1.4%	$36.14	$23.23 ▼ $40.58	$3.49B	-0.1	746,786 shs	860,570 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	-0.53%	+99.65%	+117.69%	+171.46%
DBVT DBV Technologies	0.00%	+3.78%	+4.98%	-19.97%	+47.34%
GMTX Gemini Therapeutics	+1.23%	+1.23%	+7.39%	+19.44%	+37.18%
IDYA IDEAYA Biosciences	0.00%	+9.28%	+9.49%	+36.32%	+63.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.32 -2.2%	$7.27	$2.74 ▼ $12.15	$3.47B	1.2	10.20 million shs	4.54 million shs
DBVT DBV Technologies	$14.55 +2.2%	$15.02	$8.70 ▼ $26.18	$914.83M	-0.93	363,415 shs	124,583 shs
GMTX Gemini Therapeutics	$79.81 +1.2%	$75.58	$1.16 ▼ $14.10	$3.46B	-0.12	189,291 shs	370,353 shs
IDYA IDEAYA Biosciences	$39.67 +1.4%	$36.14	$23.23 ▼ $40.58	$3.49B	-0.1	746,786 shs	860,570 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	-0.53%	+99.65%	+117.69%	+171.46%
DBVT DBV Technologies	0.00%	+3.78%	+4.98%	-19.97%	+47.34%
GMTX Gemini Therapeutics	+1.23%	+1.23%	+7.39%	+19.44%	+37.18%
IDYA IDEAYA Biosciences	0.00%	+9.28%	+9.49%	+36.32%	+63.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.71	Moderate Buy	$12.83	13.37% Upside
DBVT DBV Technologies	2.71	Moderate Buy	$48.50	233.33% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IDYA IDEAYA Biosciences	2.81	Moderate Buy	$50.13	26.35% Upside

Current Analyst Ratings Breakdown

Latest DBVT, GMTX, ABCL, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00
8/6/2026	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/6/2026	ABCL AbCellera Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $12.00
8/5/2026	IDYA IDEAYA Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $60.00
8/5/2026	IDYA IDEAYA Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$63.00 ➝ $59.00
7/17/2026	ABCL AbCellera Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	IDYA IDEAYA Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$53.00 ➝ $48.00
7/7/2026	ABCL AbCellera Biologics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$11.00
7/7/2026	IDYA IDEAYA Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$65.00 ➝ $63.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	46.20	N/A	N/A	$2.92 per share	3.88
DBVT DBV Technologies	$5.64M	162.22	N/A	N/A	$2.55 per share	5.71
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IDYA IDEAYA Biosciences	$218.71M	15.94	N/A	N/A	$13.65 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/5/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/3/2026 (Estimated)

Latest DBVT, GMTX, ABCL, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million
7/16/2026	Q2 2026	DBVT DBV Technologies	-$0.12	-$0.60	-$0.48	-$0.60	$0.90 million	$0.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
DBVT DBV Technologies	N/A	3.72	3.72
GMTX Gemini Therapeutics	N/A	71.49	71.49
IDYA IDEAYA Biosciences	N/A	10.45	10.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
DBVT DBV Technologies	71.74%
GMTX Gemini Therapeutics	75.42%
IDYA IDEAYA Biosciences	98.29%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
DBVT DBV Technologies	1.06%
GMTX Gemini Therapeutics	12.90%
IDYA IDEAYA Biosciences	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	219.53 million	Optionable
DBVT DBV Technologies	80	62.88 million	62.21 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IDYA IDEAYA Biosciences	80	87.86 million	83.73 million	Optionable

DBVT, GMTX, ABCL, and IDYA Headlines

Recent News About These Companies

Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 59,780 IDEAYA Biosciences, Inc. $IDYA

August 22 at 5:04 AM | marketbeat.com

Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

August 21 at 4:01 AM | marketbeat.com

Ideaya Biosciences, Genentech Partner for Pancreatic Cancer Trial

August 19, 2026 | finance.yahoo.com

IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

August 19, 2026 | finanznachrichten.de

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

August 19, 2026 | prnewswire.com

Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA

August 16, 2026 | marketbeat.com

Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA

August 15, 2026 | marketbeat.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of "Moderate Buy" by Brokerages

August 15, 2026 | americanbankingnews.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages

August 15, 2026 | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

August 15, 2026 | marketbeat.com

LifeSci Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

August 12, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and IDEAYA Biosciences (IDYA)

August 8, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and TransMedics Group (TMDX)

August 6, 2026 | theglobeandmail.com

The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership

August 6, 2026 | finance.yahoo.com

IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial

August 5, 2026 | marketbeat.com

IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises

August 4, 2026 | finance.yahoo.com

IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

August 4, 2026 | marketbeat.com

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

August 4, 2026 | prnewswire.com

IDEAYA Biosciences (IDYA) Expected to Post Earnings on Monday

August 3, 2026 | marketbeat.com

Dimensional Fund Advisors LP Increases Position in IDEAYA Biosciences, Inc. $IDYA

August 3, 2026 | marketbeat.com

Seven Fleet Capital Management LP Buys New Position in IDEAYA Biosciences, Inc. $IDYA

August 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, GMTX, ABCL, and IDYA Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$11.32 -0.25 (-2.16%)

As of 08/21/2026 04:00 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

DBV Technologies NASDAQ:DBVT

$14.55 +0.31 (+2.18%)

As of 08/21/2026 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Gemini Therapeutics NASDAQ:GMTX

$79.81 +0.97 (+1.23%)

As of 08/21/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

IDEAYA Biosciences NASDAQ:IDYA

$39.67 +0.56 (+1.43%)

As of 08/21/2026 04:00 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DBVT, GMTX, ABCL, and IDYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DBVT, GMTX, ABCL, and IDYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DBVT, GMTX, ABCL, and IDYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, GMTX, ABCL, and IDYA Company Descriptions

AbCellera Biologics NASDAQ:ABCL

DBV Technologies NASDAQ:DBVT

Gemini Therapeutics NASDAQ:GMTX

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DBVT, GMTX, ABCL, and IDYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DBVT, GMTX, ABCL, and IDYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DBVT, GMTX, ABCL, and IDYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, GMTX, ABCL, and IDYA Company Descriptions

AbCellera Biologics NASDAQ:ABCL

DBV Technologies NASDAQ:DBVT

Gemini Therapeutics NASDAQ:GMTX

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools